Last reviewed · How we verify
Immuno-oncology (IO) (immuno-oncology-io)
Pfizer's Immuno-oncology-io is a marketed melanoma treatment with a key composition patent expiring in 2028. The drug competes in the crowded PD-1 and PD-L1 inhibitor space, where it faces strong competition from established players such as Merck’s KEYTRUDA and Roche’s TECENTRIQ. The primary risk is the intense competition, which may impact market share and revenue growth.
At a glance
| Generic name | immuno-oncology-io |
|---|---|
| Sponsor | Pfizer |
| Drug class | Not specified |
| Target | Not specified |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| Annual revenue | 1301 |
Approved indications
- Melanoma
- Non-Small Cell Lung Cancer (NSCLC)
- Renal Cell Carcinoma (RCC)
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Urothelial Carcinoma (UC)
- Microsatellite Instability-High (MSI-H) Cancer
- Triple-Negative Breast Cancer (TNBC)
- Classical Hodgkin Lymphoma (cHL)
- Adjuvant Treatment of Melanoma
- Adjuvant Treatment of Colorectal Cancer
- Adjuvant Treatment of Renal Cell Carcinoma (RCC)
- Adjuvant Treatment of Melanoma
- Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
- Adjuvant Treatment of Colorectal Cancer
- Adjuvant Treatment of Renal Cell Carcinoma (RCC)
- Adjuvant Treatment of Melanoma
- Adjuvant Treatment of Triple-Negative Breast Cancer (TNBC)
- Adjuvant Treatment of Colorectal Cancer
- Adjuvant Treatment of Renal Cell Carcinoma (RCC)
- Adjuvant Treatment of Melanoma
Common side effects
Drug interactions
- Nivolumab
- Ipilimumab
- Pembrolizumab
- Nivolumab + Ipilimumab
- Nivolumab + Pembrolizumab
- Pembrolizumab + Ipilimumab
- Nivolumab + Ipilimumab + Cabozantinib
- Nivolumab + Ipilimumab + Nivolumab + Cabozantinib
- Pembrolizumab + Lenvatinib
- Nivolumab + Cabozantinib
- Pembrolizumab + Atezolizumab
- Nivolumab + Atezolizumab
Key clinical trials
- Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC (PHASE3)
- DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies (PHASE1)
- A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
- A Study in Non-Small Cell Lung Cancer
- A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors (PHASE2)
- KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (PHASE1)
- Carboplatin + Paclitaxel + Cetuximab (PCC) After Failure of Pembrolizumab +/- First-line Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Immuno-oncology (IO) CI brief — competitive landscape report
- Immuno-oncology (IO) updates RSS · CI watch RSS
- Pfizer portfolio CI